WO2023194796 - RECOMBINANT AAV CAPSID PROTEINS
National phase entry:
Publication Number
WO/2023/194796
Publication Date
12.10.2023
International Application No.
PCT/IB2023/000175
International Filing Date
04.04.2023
Title **
[English]
RECOMBINANT AAV CAPSID PROTEINS
[French]
PROTÉINES DE CAPSIDE DE VAA RECOMBINANT
Applicants **
VECTORY B.V.
Inventors
SANDERS, Barbara
POS, Wouter
KONSTANTINOVA, Pavlina
VAN DEVENTER, Sander
Priority Data
63/362,419
04.04.2022
US
63/366,428
15.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 16590 | |
| EPO | Filing, Examination, Granting | 722342 | |
| Japan | Filing, Examination, Granting | 7714 | |
| South Korea | Filing, Examination, Granting | 33679 | |
| USA | Filing, Examination, Granting | 119790 |
Total:
900,115
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are recombinant adeno-associated virus (AAV) capsid proteins, compositions (e.g., rAAV) comprising the capsid proteins, nucleic acids encoding the capsid proteins, and methods of making and using the capsid proteins.[French]
L'invention concerne des protéines de capside de virus adéno-associé (VAA) recombinant, des compositions (par exemple, de VAAr) comprenant les protéines de capside, des acides nucléiques codant pour les protéines de capside, et des procédés de fabrication et des méthodes d'utilisation des protéines de capside.